Solventum (SOLV) valuation
Solventum P/E ratio history
Solventum trades at 9.9 times its earnings over the last twelve months and 11.3 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $79.24 | $8.88 | 8.9 | 12.7 |
| Dec 31, 2024 | $66.06 | $2.76 | 23.9 | 11.4 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Solventum valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| SolventumSOLV | $14.1B | 9.9 | 11.3 | 1.7 |
| DaVitaDVA | $12.0B | 13.9 | 11.4 | 0.8 |
| Universal Health ServicesUHS | $10.7B | 7.2 | 7.5 | 0.6 |
| Henry ScheinHSIC | $9.67B | 24.8 | 14.9 | 0.7 |
| Quest DiagnosticsDGX | $27.8B | 25.1 | 21.3 | 2.4 |
| LabcorpLH | $29.6B | 29.7 | 18.6 | 2.1 |
| Hims & Hers HealthHIMS | $6.41B | — | — | 2.5 |
| CenteneCNC | $33.8B | 22.7 | 12.6 | 0.2 |
| HumanaHUM | $49.8B | 39.1 | 31.6 | 0.3 |
| Peer median | 24.8 | 14.9 | 0.8 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: SOLV financials · SOLV returns
No forecast, no recommendation. This page describes Solventum from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.